89667Fudan University Shanghai Cancer Center, Shanghai, China.
Shanghai Medical College, 58305Fudan University, Shanghai, P.R. China.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211064900. doi: 10.1177/10760296211064900.
Cancer patients experience an increased risk of venous thromboembolism (VTE). In this study, we investigated a risk of venous thromboembolism algorithm (RVTA) in patients with colorectal cancer and evaluated its ability to predict the prognosis of colorectal cancer. We retrospectively analyzed clinical data from 345 patients with colorectal cancer from January 2015 to December 2018 at the Shanghai Cancer Center to develop the RVTA. Additionally, the 345 patients were followed until December 2020 for prognostic analysis. The RVTA included the following variables: (a) platelet count, (b) blood transfusion history, (c) metastasis, (d) multiple chemotherapy regimens, and (e) the D-dimer level. Good predictive efficiency was observed for the RVTA (AUC was 0.825; 95% CI was 0.721 to 0.930). The median progression-free survival (PFS) of patients who had a score less than 4 (0-3), defined as the low-risk group, was significantly longer than that of the high-risk group, which included patients who had a score greater than 4 (4-8) (26 vs ten months, < .001). The RVTA was a valuable predictor for VTE risk and had prognostic value in colorectal cancer.
癌症患者发生静脉血栓栓塞症(VTE)的风险增加。在这项研究中,我们研究了结直肠癌患者的静脉血栓栓塞风险算法(RVTA),并评估了其预测结直肠癌预后的能力。我们回顾性分析了 2015 年 1 月至 2018 年 12 月在上海癌症中心就诊的 345 例结直肠癌患者的临床资料,以开发 RVTA。此外,这 345 例患者随访至 2020 年 12 月进行预后分析。RVTA 包括以下变量:(a)血小板计数,(b)输血史,(c)转移,(d)多种化疗方案,和(e)D-二聚体水平。RVTA 具有良好的预测效率(AUC 为 0.825;95%CI 为 0.721 至 0.930)。评分低于 4 分(0-3 分)的患者的中位无进展生存期(PFS)明显长于评分大于 4 分(4-8 分)的患者(26 个月比 10 个月, < 0.001)。RVTA 是 VTE 风险的有价值预测指标,在结直肠癌中有预后价值。